<DOC>
	<DOCNO>NCT01830673</DOCNO>
	<brief_summary>The primary endpoint induction T-regulatory cell specific subcutaneous immunotherapy ( SCIT ) . Patients suffer grass pollen allergy ( relevant clinical symptomes pollen season , Skin Prick test diamter &gt; 4mm RAST class II high ) include . The patient allocate three study group : Group 1 : directly SCIT ( completion 2nd 3rd year treatment ) Group 2 : complete SCIT three year ago Group 3 : Patients clinically relevant grass pollen allergy without SCIT . The investigator analyze lung function parameter , exhale NO ( eNO ) ask patient record symptoms adjacent pollen season . A blood sample drawn analyze amount TH1 TH2 regulatory T-cells , inflammatory marker ( IL-2 , IL-5 , IL-10 , IL-12/23 , TNF-alpha , IFN-gamma ) block antibody ( IgG , IgG4 ) .</brief_summary>
	<brief_title>Regulatory T-cells After Subcutaneous Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>informed consent , clinically relevant grass pollen allergy , age &gt; 6 &lt; 28 severe unstable asthma , regular ingestion antihistamine , systemic steroid therapy , lung funtcion VC &lt; 70 % , FEV1 &lt; 65 %</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>28 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>T-regulatory cell</keyword>
	<keyword>TH1 , TH2 cell</keyword>
	<keyword>specific IgE</keyword>
	<keyword>specific IgG</keyword>
	<keyword>specific IgG4</keyword>
	<keyword>IL2</keyword>
	<keyword>IL5</keyword>
	<keyword>IL10</keyword>
	<keyword>IL12/23</keyword>
	<keyword>Y-IFN</keyword>
	<keyword>TNF-a</keyword>
</DOC>